8-K: Tvardi Therapeutics Announces First Quarter 2025 Results and Provides Business Update

Tvardi Therapeutics reports its first quarter 2025 results, highlighting the completion of its merger with Cara Therapeutics and providing a business update on its clinical programs.

Summary

• Tvardi Therapeutics announced its first quarter 2025 financial and operating results.
• The company completed its merger with Cara Therapeutics, receiving approximately $23.8 million in net cash.
• This is in addition to the $28.3 million raised in a December 2024 private placement.
• Tvardi anticipates its cash runway will be sufficient to fund operations into the second half of 2026, approximately one year post data readouts in IPF.
• The company is on track for multiple Phase 2 data readouts with its STAT3 inhibitor, TTI-101, with the lead program in IPF expected in the second half of 2025.
• An IND submission is planned for its second clinical candidate, TTI-109, in the first half of 2025.
• Preliminary topline data from the REVERT Liver Cancer Phase 1b/2 clinical trial of TTI-101 is anticipated in the first half of 2026.
• Ernst & Young LLP (EY) was dismissed as the company's independent registered public accounting firm on May 12, 2025.
• Deloitte & Touche LLP (Deloitte) was approved as the company's new independent registered public accounting firm for the fiscal year ending December 31, 2025.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive due to the successful merger, sufficient cash runway, and progress in clinical trials. However, the inherent risks associated with drug development and the company's history of net losses temper the overall sentiment.

Positives

• The merger with Cara Therapeutics provides Tvardi with approximately $23.8 million in net cash.
• The company believes it is well financed through meaningful value inflection points.
• The anticipated cash runway is expected to be sufficient to fund operations into the second half of 2026.
• The company is on track for multiple Phase 2 data readouts with its STAT3 inhibitor, TTI-101.
• The Nasdaq listing has heightened the company's visibility and potential access to capital.

Risks

• The company has incurred significant net losses since inception.
• The company's product candidates are subject to uncertainties associated with clinical development and regulatory approval.
• The company may require additional capital to continue to advance its product candidates.
• The company relies on third parties, contract manufacturers, and contract research organizations.
• The company may be adversely affected by other economic, business, or competitive factors.

Future Outlook

The company anticipates its cash runway will be sufficient to fund operations into the second half of 2026, approximately one year post data readouts in IPF. They are on track for multiple Phase 2 data readouts with its STAT3 inhibitor, TTI-101, with the lead program in IPF expected in the second half of 2025. An IND submission is planned for its second clinical candidate, TTI-109, in the first half of 2025. Preliminary topline data from the REVERT Liver Cancer Phase 1b/2 clinical trial of TTI-101 is anticipated in the first half of 2026.

Management Comments

• Dr. Imran Alibhai, Chief Executive Officer of Tvardi, stated, 'While it has only been a few weeks since we completed our merger with Cara Therapeutics, our Nasdaq listing has heightened our visibility and potential access to capital.'
• Dr. Imran Alibhai stated, 'With the cash on our balance sheet, we believe we are well financed through meaningful value inflection points, including anticipated Phase 2 readouts of our lead program in idiopathic pulmonary fibrosis (IPF) as well as our hepatocellular carcinoma program.'

Industry Context

Tvardi's focus on STAT3 inhibition as a therapeutic target aligns with broader industry interest in novel approaches to treat fibrosis-driven diseases and cancer. The company's clinical programs in IPF and hepatocellular carcinoma address areas with significant unmet medical need, potentially positioning them favorably in the biopharmaceutical landscape.

Comparison to Industry Standards

• Many biopharmaceutical companies are focused on developing therapies for fibrotic diseases, including IPF, with companies like Boehringer Ingelheim and Roche already having approved treatments.
• Tvardi's approach of targeting STAT3 is distinct from some other approaches, which may offer a competitive advantage if successful.
• The company's cash runway into 2H 2026 is a critical factor, as many biotech companies need to raise additional capital to fund ongoing clinical trials.

Stakeholder Impact

• Shareholders: The merger and clinical trial progress could positively impact shareholder value.
• Employees: The company's financial stability and clinical advancements could improve job security and opportunities.
• Patients: Successful development of TTI-101 and TTI-109 could provide new treatment options for fibrosis-driven diseases and cancer.

Next Steps

• Investigational New Drug (IND) submission planned for its second clinical candidate, TTI-109, in 1H 2025.
• Data from the company's ongoing REVERT IPF Phase 2 clinical trial of TTI-101 anticipated in 2H 2025.
• Preliminary topline data from the company's ongoing REVERT Liver Cancer Phase 1b/2 clinical trial of TTI-101 anticipated in 1H 2026.

Key Dates

Keywords

Tvardi Therapeutics, Cara Therapeutics, STAT3 inhibitor, TTI-101, TTI-109, Idiopathic Pulmonary Fibrosis, Hepatocellular Carcinoma, Merger, Phase 2, Clinical Trials, Financial Results